Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | -5.46% | -11.42% | -3.43% |
06-07 | Top Premarket Gainers | MT |
06-05 | VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.43% | 32.69M | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
+11.88% | 216B | |
-0.78% | 219B | |
+5.90% | 164B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Menlo Therapeutics Inc. Announces Board Changes